

# **ENCAPSULATION BY MEMBRANE EMULSIFICATION**


**Dr Marijana M. Dragosavac  
and  
Professor Richard Holdich**

**Department of Chemical Engineering, Loughborough University,  
Leicestershire, U.K.**

## PRESENTATION LAYOUT


- § **Produce drops (convert to encapsulated particles)**
- § **Membrane surface, what makes a good membrane?**
- § **Membrane emulsification – shear and size**
- § **Examples – from drops to particles, including surfactant free drops and yeast encapsulation**

# CONVENTIONAL MEMBRANES




# MEMBRANE EMULSIFICATION

## NO SHEAR STRESS ON THE MEMBRANE SURFACE



Scaling up – **possible**  
Productivity – **high**

TOP VIEW



Hydrophilic membrane

$D_{50}=200 \mu\text{m}$

*Kosvintsev et al. 2008*

# **SHEAR STRESS ON THE MEMBRANE SURFACE**

## **Movements of continuous phase:**

§ **STIRRING**

§ **CROSS FLOW**

§ **PULSING THE CONTINUOUS PHASE**




## **Movements of the membrane:**

§ **VIBRATION (axial oscillation)**


§ **ROTATION**

§ **AZIMUTHAL (TORSIONAL)**

# STIRRING - DISPERSION CELL




# STIRRING - DISPERSION CELL




**pressure** drop is very low, due to the membrane design, the shear is low and emulsification conditions are gentle


13




38




68



105





146 dynes/cm<sup>2</sup>





# FORCE BALANCE MODEL



$F_{ca}$  - Capillary force

$$F_{ca} = f(g, r_p)$$

$F_d$  - Drag force

$$F_d = f(t_{max}, r_p, d_d)$$

$$t_{max} = 0.825hwr_{trans} \frac{1}{d}$$

$$pd_p g = 9pt_{max} d_d \sqrt{\frac{\rho_l d_d \dot{\omega}^2}{2 \rho} - r_p^2}$$



$$d_d = f(r_p, t_{max}, g)$$

*Kosvintsev et al. 2008*

*Dragosavac et al. 2008*




## STIRRING - DISPERSION CELL

$$x = \frac{\sqrt{18t^2 r_p^2 + 2\sqrt{81t^4 r_p^4 + 4r_p^2 t^2 g^2}}}{3t}$$


**Drop diameter** (points to  $x$ )  
**Shear stress** (points to  $t$ )  
**Pore radius** (points to  $r_p$ )  
**Interfacial tension** (points to  $g$ )

# STIRRING - DISPERSION CELL




# SHEAR STRESS ON THE MEMBRANE SURFACE

## OSCILLATION AXIAL SYSTEM



Holdich R. G. et. al. 2010




**Shear stress**

$$t_{\max} = f(h, f, a)$$

DOES CHANGE WITH TIME AND IT DOES NOT CHANGE OVER THE MEMBRANE AREA


# SHEAR STRESS ON THE MEMBRANE SURFACE

## PULSING THE LIQUID FLOW



*Holdich R. G. et. al. 2010*

*Piacentini. et. al. 2014*




**Shear stress**

$$t_{\max} = f(h, f, a)$$

# SHEAR STRESS BY PULSING LIQUID FLOW

*coacervates dyed with blue food colouring:*



# SHEAR STRESS ON THE MEMBRANE SURFACE

## OSCILLATING (AZIMUTHAL) SYSTEM


### Oscillating Membrane Emulsification

- **Pharma / high value**
  - Current capacity: 4 kg/hour,
- **FMCG market**
  - Current capacity: 100 kg/hour,



# **SHEAR STRESS ON THE MEMBRANE SURFACE**

## **OSCILLATING (AZIMUTHAL) SYSTEM**





# **EXPERIMENTAL RESULTS**

## **FORMULATIONS**

**1. COMPLEX COACERVATION**

**2. POLYMER PARTICLES FOR DRUG DELIVERY**

**3. INORGANIC SILICA PARTICLES**

**4. SURFACTANT FREE STABILISATION**

**5. YEAST ENCAPSULATION**

# **1. COMPLEX COACERVATION**

## **O/W emulsion**

**Please see poster:  
Alix Barton**

# 1. COMPLEX COACERVATION

## O/W emulsion

### Motivation for the work:


**Currently batch production**

**High polydispersity of the product and usually too big droplet size**

**Need for pig gelatine alternative**


# 1. COMPEX COACERVATION

1. **Drop production** in hydrocolloids solution
2. Coacervation (phase separation) implying the formation of a coacervate phase – **pH adjustment**
3. Wall formation by aggregation of the hydrocolloid around droplets of the emulsified hydrophobic material – **time, room temperature**
4. **Wall-hardening**, which is generally achieved by cross-linking the hydrocolloid forming the wall




# 1. COMPLEX COACERVATION – Oil encapsulation


## LIQUID CRYSTALS



Fast cooling




Slow cooling




*Dragosavac 2012, Unpublished material*

## ENCAPSULATION OF ESSENTIAL OILS



## ENCAPSULATION OF PARAFFIN OIL




*Dragosavac 2012, Unpublished material*

Optimising drying methods – longer storage

# 1. COMPLEX COACERVATION – Oil encapsulation

## FISH GELATINE CAPSULES

### WHY FISH GELATINE?


- **ROOM TEMPERATURE** - less energy compared to alternative gelatine types and 
- New possibilities for encapsulation of **VOLATILE COMPOUNDS**
- Increased **CONSUMER** consent for religious or diet reasons and health safety

*Piaccentini et al., 2013*

*ITM-CNR @ University  
of Calabria, Rende*

# DIFFERENT RATIOS OF FG:GA FOR MICROCAPSULES

ROOM TEMPERATURE




*Piaccentini et al.,  
2013*

**FG:GA** (a) 30:70; (b) 40:60; (c) 80:20; and (d) 50:50.



# OIL ENTRAPMENT



**Freeze dried particles  
(to enable future  
volatile compound  
encapsulation)**

**Silica particles added to  
produce free flowing  
particles**

*Piaccentini et al., 2013*


# 1. COMPLEX COACERVATION

## DISPERSION CELL, PULSING & VIBRATING SYSTEMS

Dispersed phase: **Sunflower oil**

Continuous phase: **Fish gelatine (FG) and Gum Arabic (GA)**

20  $\mu\text{m}$  MEMBRANE



Piaccentini et al., 2013

Flux through the pulsed membrane up to 30 L h<sup>-1</sup>


## 2. ANTICANCER DRUG ENCAPSULATION

Aim to encapsulate water soluble peptide

## 2. Poly (D,L-Lactic-Glycolic Acid): PLGA

- § FDA approved biocompatibility
- § Complete degradation
- § Current applications:
  - § Anticancer drug carrier
  - § Human growth deficiency treatments
  - § Protein and gene delivery
  - § Scaffolds for bone repairing
  - § Suture material

**Secondary emulsion  
W/O/W**



## 2. ANTICANCER DRUG ENCAPSULATION O/W & W/O/W

### Motivation for the work:

Currently batch production

Low uniformity of the produced particles using conventional emulsification methods, *expensive losses of product*

Need for higher encapsulation efficiency

Anticancer drug - extremely expensive & shear/temperature sensitive


## **2. ENCAPSULATION OF WATER SOLUBLE PEPTIDE USING BIODEGRADABLE POLYMER**

### **SOLVENT EVAPORATION**


- 1. Dispersion phase – polymer (PLGA) mixed with DCM (volatile oil phase)**
- 2. Mixing the peptide with previously prepared dispersion phase**
- 3. Injecting through the membrane into 1% PVA solution**
- 4. DCM will evaporate from the particles leaving only peptide within the spherical PLGA particles**

## 2. ENCAPSULATION OF WATER SOLUBLE PEPTIDE USING BIODEGRADABLE POLYMER

### O/W EMULSIONS



### W/O/W EMULSIONS



#### HPLC - ENCAPSULATION EFFICIENCY (EE) OF PEPTIDE

<b>üCancer treatment</b>	POLYMER CONCENTRATION (%)	EE (%)
COSOLVENT METHOD (O/W)	10	40
	20	50
<b>W/O/W</b>	10	70
	20	<b>85</b>



Commercially available  
14 day kit  
(~1g particles/ 70mg peptide)

**~200€**


*Dragosavac 2012,  
Unpublished material*




## 2. ENCAPSULATION OF WATER SOLUBLE PEPTIDE USING BIODEGRADABLE POLYMER

**W/O/W  
EMULSIONS**


**O/W  
EMULSIONS**




a



b



c



d


**W/O/W  
emulsions  
encapsulation  
efficiency  
close to 100%**

*G. Gasparini et. al, 2010, Colloids and Surfaces B: Biointerfaces*


### **3. SILICA PARTICLES W/O emulsion**

Aim to produce spherical silica particles  
with high surface area and internal structure




# 3. SILICA PARTICLES



**SILICA PARTICLES WITH D<sub>50</sub>=40μm AFTER DRYING**  
SEM at Loughborough Materials Characterization Centre



**AGING OF THE HYDROGEL IN DIFFERENT SOLVENTS**



## **4. SURFACTANT FREE PARTICLES**

### **O/W emulsion**

**Aim to produce encapsulated and functional particles  
for photocatalysis**


## 4. SURFACTANT FREE STABILISATION



A Pickering emulsion (Ramsden)

*surfactant free*

## 4. SURFACTANT FREE STABILISATION



*surfactant free*




## **5. YEAST ENCAPSULATION**

### **W/O emulsion**

Aim to produce encapsulated particles  
capable of drug delivery surviving gastric juices




## 5. YEAST ENCAPSULATION



Please see poster:  
Serena Morelli

# WHY MEMBRANE EMULSIFICATION?

- § Low energy process
- § Low pressure process
- § Formulation is still key
- § Small-scale through to production
- § Variety of shear techniques:
  - § Mainly stirred cell and oscillation/pulsation
- § Good for multiple emulsions and continuous production
- § Small & large drop: encapsulation and functionalised particles
- § Good encapsulation of shear/temperature sensitive compounds



## ACKNOWLEDGEMENTS

**Micro / Nano – Materials Engineering Group,**

*Prof. Richard G. Holdich*

*Dr Marijana M. Dragosavac*

*Dr Goran T. Vladisavljevic*

*Microchannel Array Engineering Team,*

*National Food Research Institute, Tsukuba, Japan.*

*Prof. Mitsutoshi Nakajima*



### *Visiting researchers:*

*Emma Piaccentini, CNR Italy,*

*Alessandra Imbrognio, CNR Italy*

*Miguel Angel Suarez Valdes, UNIDAV, Spain*

**For the membranes:**



### *Current Research Students & PostDocs:*

*Serena Morelli,*

*Alix Barton,*

*Rahimah Othman,*

*Konstantin Loponov...*

<http://www.micropore.co.uk/>

**Micropore**  
**Technologies Ltd. UK**

**Funding:**

**EPSRC**

Engineering and Physical Sciences  
Research Council

**TSB**